Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure

Digestive Diseases and Sciences

Volumn 51, Issue 12, 2006, Pages 2316-2321

  Yahav, Jacob ^a,c   Samra, Zmira ^a,c   Niv, Yaron ^a,c   Evans, Charlesnika T ^d   Passaro, Douglas J ^d   Dinari, Gabriel ^a,b,c   Shmuely, Haim ^a,c,e  

^a RABIN MEDICAL CENTER   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e Helicobacter pylori Research Institute   (Israel)

Author keywords

Culture guided therapy; Helicobacter pylori; Treatment failure

Indexed keywords

ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE;

ANTIBIOTIC RESISTANCE; ARTICLE; BIOPSY; CELL CULTURE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE PREDISPOSITION; DRUG EFFECT; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PATHOLOGY; PREVALENCE; STOMACH; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BIOPSY; CELLS, CULTURED; CLARITHROMYCIN; COHORT STUDIES; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PREVALENCE; STOMACH; TREATMENT FAILURE;

EID: 33846997883     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-006-9302-2     Document Type: Article

References (25)

1. Osato MS (2000) Antimicrobial susceptibility testing for Helicobacter pylori: sensitivity test results and their clinical relevance. Curr Pharm Des 6:1545-1555
2. Graham DY, Qureshi WA (2000) Antibiotic-resistant H. pylori infection and its treatment. Curr Pharm Des 6:1537-1544
3. Tompkins DS, Perkin J, Smith C (1997) Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 2:185-187
4. Megraud F (2004) H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374-1384
5. Samra Z, Shmuely H, Niv Y, Dinari G, Passaro DJ, Geler A, Gal E, Fishman M, Bachor J, Yahav J (2002) Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. J Antimicrob Chemother 49:1023-1026
6. King A (2001) Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrobial Chemother 48:77-80
7. Goh KL, Parasakthi N, Chuah SY, Cheah PL, Lo YL, Chin SC (1997) Comparison of two 1-week low-dose omeprazole triple therapies-optimal treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 11:1115-1118
8. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W (1998) Primary and 8. acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin influence on treatment outcome. Am J Gastroenterol 93:386-389
9. Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L, Alampi G, Nicolini G, Sottili S, Simoni P, Roda A, Roda E (1998) Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 12:439-445
10. Buckley MJ, Xia HX, Hyde DM, Keane CT, O'Morain CA (1997) Metronidazole 10. resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. DigDis Sci 42:2111-2115
11. Harris AW, Pryce DI, Gabe SM, Karim QN, Walker MM, Langworthy H, Baron JH,MIsiewicz JJ (1996) Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther 10:1005-1008
12. Misiewicz JJ, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, Kerr GD, Dion FJ, Langworthy H, Piper D (1997) One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 41:735-749
13. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group (EHPSG) (2002) Current concepts in themanagement of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180
14. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, WU JJ (2003) Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther 8:347-353
15. Miwa H, Nagahara A, Kurosawa A, Ohkusa T, Ohkura R, Hojo M, Enomoto N, Sato N (2003) Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection? Aliment Pharmacol Ther 15:1545-1551
16. Lamouliatte H, Megraud F, Delchier JC, Bretagne JF, Courillon-Mallet A, De Korwin JD, Fauchere JL, Labigne A, Flejou JF, Barthelemy P, Multicentre Study Group (2003) Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment Pharmacol Ther 15:791-797
17. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN(1999)Asystematic reviewof Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13:1047-1055
18. Lerang F, Moum B, Haug JB, Berge T, Tolas P, Sandvei PK, Torp R, Tonnesen T (1997) Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: Does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 92:248-253
19. Fock KM, Chelvam P, Lim SG (2000) Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment Pharmacol Ther 14:225-231
20. Moayyedi P, Ragunathan PL,Mapstone N, AxonAT, Tompkins DS (1998) Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 33:62-65
21. Lind T, Megraud F,Unge P, Bayerdorffer E, O'Morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, HellblomM, Wrangstadh M, Zeijlon L, Cederberg C (1999) The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253
22. van derWouden EJ, Thijs JC, van Zwet AA, SluiterWJ, Kleibeuker JH (1999) The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 94:1751-1759
23. Prazeres Magalhaes P, De Magalhaes Queiroz DM, Campos Barbosa DV, Aguiar Rocha G, Nogueira Mendes E, Santos A, Valle Correa PR, Camargos Rocha AM, Martins Teixeira L, Affonso de Oliveira C (2002) Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 46:2021-2023
24. Osato MS, Reddy R, Graham DY (1999) Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 12:341-3417
25. Bazzoli F, Zagari RM, Pozzato P, Fossi S, Ricciardiello L, Nicolini G, De Luca L, Berretti D, ALampi G, Did Pietro C, Morelli P, Roda E (2002) Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 6:153-158